ATE415421T1 - Deamidiertes interferon-beta - Google Patents

Deamidiertes interferon-beta

Info

Publication number: ATE415421T1
Authority: AT; Austria
Prior art keywords: deamidated; beta; interferon; interferon beta; native
Prior art date: 2004-11-10

Application number

AT05818235T

Other languages

English (en)

Inventor

Kenji Furuya

Deborah Johnson-Jackson

Diana Ruscio

Original Assignee

Novartis Vaccines & Diagnostic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-10

Filing date

2005-11-10

Publication date

2008-12-15

2005-11-10 Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic

2008-12-15 Application granted granted Critical

2008-12-15 Publication of ATE415421T1 publication Critical patent/ATE415421T1/de

Links

102000003996 Interferon-beta Human genes 0.000 title abstract 3
108090000467 Interferon-beta Proteins 0.000 title abstract 3
229960001388 interferon-beta Drugs 0.000 title abstract 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
101001054334 Homo sapiens Interferon beta Proteins 0.000 abstract 1
229960001230 asparagine Drugs 0.000 abstract 1
235000009582 asparagine Nutrition 0.000 abstract 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002255 enzymatic effect Effects 0.000 abstract 1
238000010348 incorporation Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000029983 protein stabilization Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
238000003908 quality control method Methods 0.000 abstract 1
238000012113 quantitative test Methods 0.000 abstract 1
238000004007 reversed phase HPLC Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT05818235T 2004-11-10 2005-11-10 Deamidiertes interferon-beta ATE415421T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US62683704P	2004-11-10	2004-11-10

Publications (1)

Publication Number	Publication Date
ATE415421T1 true ATE415421T1 (de)	2008-12-15

Family

ID=36337216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05818235T ATE415421T1 (de)	2004-11-10	2005-11-10	Deamidiertes interferon-beta

Country Status (16)

Country	Link
US (2)	US7595040B2 (de)
EP (1)	EP1809662B1 (de)
JP (1)	JP4891250B2 (de)
KR (1)	KR101330626B1 (de)
CN (1)	CN101056890B (de)
AT (1)	ATE415421T1 (de)
AU (1)	AU2005304486B2 (de)
BR (1)	BRPI0517697A (de)
CA (1)	CA2587061C (de)
DE (1)	DE602005011321D1 (de)
ES (1)	ES2318575T3 (de)
MX (1)	MX2007004990A (de)
PL (1)	PL1809662T3 (de)
PT (1)	PT1809662E (de)
RU (1)	RU2404190C2 (de)
WO (1)	WO2006053134A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030190307A1 (en)	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
KR20090047452A (ko) *	2006-08-08	2009-05-12	노바티스 백신즈 앤드 다이아그노스틱스, 인크.	생물학적 활성이 증강된 재조합 인터페론-베타
CN103965347B (zh)	2007-05-02	2017-07-18	Ambrx公司	经修饰干扰素β多肽和其用途
US8273561B2 (en) *	2007-10-05	2012-09-25	Nuron Biotech, Inc.	High pressure treatment of aggregated interferons
EP3126379B1 (de) *	2014-04-04	2019-05-22	Ares Trading SA	Neuartige ifn-beta-proteinanaloga
RU2739261C1 (ru) *	2019-12-31	2020-12-22	Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН)	Способ количественного определения антипролиферативной активности интерферона-бета человека

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4737462A (en) *	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) *	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
GB9111902D0 (en) *	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
US20030190307A1 (en) *	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
IL130524A (en) *	1996-12-24	2005-08-31	Biogen Idec Inc	Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same
US6696423B1 (en) *	1997-08-29	2004-02-24	Biogen, Inc.	Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
DE59811910D1 (de) *	1997-09-23	2004-10-07	Rentschler Biotech Gmbh	Flüssige Interferon-Beta Formulierungen
EP1204682B1 (de) *	1999-07-28	2010-11-17	Genentech, Inc.	Zusammensetzungen und verfahren zur behandlung von tumoren
ES2180416B1 (es) *	2001-03-12	2004-06-01	BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A.	Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
UY27373A1 (es) *	2001-07-09	2003-02-28	Schering Ag	Formulaciones de interferón beta-humano
RU2216345C1 (ru) *	2002-03-21	2003-11-20	Закрытое Акционерное Общество "Биокад"	Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием
KR100541850B1 (ko) *	2003-03-31	2006-01-11	삼성정밀화학 주식회사	인간 인터페론-베타 변이체 및 그의 제조방법

2005
- 2005-11-10 AT AT05818235T patent/ATE415421T1/de active
- 2005-11-10 DE DE602005011321T patent/DE602005011321D1/de not_active Expired - Lifetime
- 2005-11-10 WO PCT/US2005/040758 patent/WO2006053134A2/en not_active Ceased
- 2005-11-10 BR BRPI0517697-2A patent/BRPI0517697A/pt not_active IP Right Cessation
- 2005-11-10 MX MX2007004990A patent/MX2007004990A/es active IP Right Grant
- 2005-11-10 US US11/271,516 patent/US7595040B2/en not_active Expired - Fee Related
- 2005-11-10 CN CN2005800381182A patent/CN101056890B/zh not_active Expired - Fee Related
- 2005-11-10 AU AU2005304486A patent/AU2005304486B2/en not_active Ceased
- 2005-11-10 KR KR1020077011869A patent/KR101330626B1/ko not_active Expired - Fee Related
- 2005-11-10 CA CA2587061A patent/CA2587061C/en not_active Expired - Fee Related
- 2005-11-10 ES ES05818235T patent/ES2318575T3/es not_active Expired - Lifetime
- 2005-11-10 RU RU2007121515/04A patent/RU2404190C2/ru not_active IP Right Cessation
- 2005-11-10 PT PT05818235T patent/PT1809662E/pt unknown
- 2005-11-10 EP EP05818235A patent/EP1809662B1/de not_active Expired - Lifetime
- 2005-11-10 PL PL05818235T patent/PL1809662T3/pl unknown
- 2005-11-10 JP JP2007540208A patent/JP4891250B2/ja not_active Expired - Fee Related
2009
- 2009-03-25 US US12/410,540 patent/US20090263355A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP4891250B2 (ja)	2012-03-07
CN101056890B (zh)	2012-05-09
RU2007121515A (ru)	2008-12-20
KR101330626B1 (ko)	2013-11-18
JP2008519769A (ja)	2008-06-12
PL1809662T3 (pl)	2009-07-31
WO2006053134A3 (en)	2006-08-31
EP1809662A2 (de)	2007-07-25
RU2404190C2 (ru)	2010-11-20
DE602005011321D1 (de)	2009-01-08
WO2006053134A2 (en)	2006-05-18
KR20070084559A (ko)	2007-08-24
AU2005304486A1 (en)	2006-05-18
CA2587061A1 (en)	2006-05-18
CA2587061C (en)	2011-08-16
MX2007004990A (es)	2007-06-14
US20090263355A1 (en)	2009-10-22
ES2318575T3 (es)	2009-05-01
BRPI0517697A (pt)	2008-10-14
US20060120998A1 (en)	2006-06-08
AU2005304486B2 (en)	2011-08-11
US7595040B2 (en)	2009-09-29
CN101056890A (zh)	2007-10-17
PT1809662E (pt)	2009-02-26
EP1809662B1 (de)	2008-11-26

Legal Events

Date

Code

Title

Description

2009-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1809662

Country of ref document: EP

Publication	Publication Date	Title
DE60042122D1 (de)	2009-06-10	Fibroblasten wachstumsfaktor-ähnliche polypeptide
NO2017028I1 (no)	2017-06-23	eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
BRPI0514790A (pt)	2008-06-24	muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
CY1114030T1 (el)	2016-07-27	Ομοιογενη παρασκευασματα toy il-29
NZ754961A (en)	2022-04-29	Growth differentiation factor 15 (gdf-15) constructs
BRPI0416683A (pt)	2007-01-30	muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
ATE417595T1 (de)	2009-01-15	Keratin-bindende polypeptide
DE68929043D1 (de)	1999-09-09	Für androgen-rezeptor-protein kodierende dna
ATE540973T1 (de)	2012-01-15	Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
MXPA05008704A (es)	2005-10-05	Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
Guo et al.	2015	Molecular cloning and characterization of a novel bovine IFN-ε
ATE415421T1 (de)	2008-12-15	Deamidiertes interferon-beta
Ketscher et al.	2015	ISG15 uncut: Dissecting enzymatic and non-enzymatic functions of USP18 in vivo
MX2009001348A (es)	2009-05-11	Interferon-beta recombinante con actividad biologica mejorada.
NZ562436A (en)	2010-01-29	Toll-like receptor 14 (TLR14) and use thereof
WO2008041014A3 (en)	2008-07-31	Interferon- alpha constructs for use in the treatment of diseases characterised by abnormal cell proliferation such as cancer
MX2009007248A (es)	2009-08-17	Peptidos bio-activos cortos para modulacion celular e inmunologica.
Andersen et al.	2013	Peginterferon lambda-1a, a new therapeutic for hepatitis C infection, from bench to clinic
ES2088911T3 (es)	1996-10-01	Gen de la proteasa i de achromobacter y el producto de este gen.
Tsygankov et al.	2014	Synthesis of recombinant gamma interferons resistant to proteolysis in the yeast Pichia pastoris
KR880701073A (ko)	1988-07-25	제조합 dna 기법에 의해 생성된 민악티빈
TW200722104A (en)	2007-06-16	Low-toxicity, long-circulating human interferon-α analogs
ATE420890T1 (de)	2009-01-15	Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
ATE475099T1 (de)	2010-08-15	Beurteilung der biologischen aktivität von hgf (hepatocyte growth factor)
DE602004019556D1 (de)	2009-04-02	Neues plexin-polypeptid, dieses codierende dna und verwendung davon